Table 2—

Characteristics of epoprostenol treatment

PatientAge/sexDuration# monthsTime monthsDuration+ monthsEpoprostenol dosage§ ng·kg−1·min−1Clinical response
A58/M24122629Stable
B43/M1232521Stable
C59/M1262221Stable
D37/F612318Improvement
E45/M9<1210Improvement
F34/F36<1412Improvement
G54/M12<1418Progression
H27/M84931Progression
I59/F66316Progression
  • M: male

  • F: female

  • #: of symptoms prior to diagnosis

  • : between diagnosis and start of epoprostenol

  • +: of epoprostenol therapy

  • §: prior to endarterectomy